AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Natural casings are produced and sold almost exclusively by the hank which is a unit of measure that is 91 meters long. A hank can consist of a varying number of strands (individual pieces of casing) which vary in length from 2 meters (which is the shortest length sold for commercial use) to as long as 28 meters. Each casing manufacturer has various "put ups" which dictate the maximum number of strands and the minimum length of each strand allowed in the put up. Casings are selected for size which is measured in millimeters and refers to the diameter of the casing; this is done exclusively by hand and is primarily done in China due to the availability of low cost labor. Commercially casings are available in various forms of packaging which are suited to different applications. Sheep/lamb and hog are available in all packaging types due to the high demand and long length of pieces; due to the shorter length and much lower demand for beef casings they are primarily only available loose or in net packs either salted or in brine.
== Molecular mechanisms in skin aging == Many dissimilar models have been used to explain skin aging on a molecular basis, such as the theory of cellular senescence, the reduction of the cells' DNA repair capacity, the loss of telomeres, oxidative stress, etc. It is believed that external factors cause a large portion of skin aging, while only 3% is caused by hereditary genetic influences. The following sections discuss prominent models and advancements in molecular mechanism studies related to skin aging.
Several studies have demonstrated that tendons respond to changes in mechanical loading with growth and remodeling processes, much like bones. In particular, a study showed that disuse of the Achilles tendon in rats resulted in a decrease in the average thickness of the collagen fiber bundles comprising the tendon. In humans, an experiment in which people were subjected to a simulated micro-gravity environment found that tendon stiffness decreased significantly, even when subjects were required to perform restiveness exercises. These effects have implications in areas ranging from treatment of bedridden patients to the design of more effective exercises for astronauts.
== Features == Each issue includes a "Making-of" article on a particular game, usually including an interview with one of the original developers. Issue 143 introduced the "Time Extend" series of retrospective articles. Like the "making-of" series, each focuses on a single game and, with the benefit of hindsight, gives an in-depth examination of its most interesting or innovative attributes. "Codeshop" examines more technical subjects such as 3D modelling programs or physics middleware, while "Studio Profile" and "University Profile" are single-page summaries ("like Top Trumps, but for game dev") of particular developers or publishers, and game-related courses at higher education institutions. Although an overall list of contributors is printed in each issue's indicia, the magazine typically has not used bylines to credit individual writers to specific reviews and articles, instead only referring to the anonymous Edge as a whole. Since 2014, some contributed features are credited with a byline. The magazine's regular columnists have been consistently credited throughout the magazine's run. The current columnists are James Leach, Clint Hocking and Tadhg Kelly. In addition, several columnists appear toward the beginning of the magazine to talk about the game industry as a whole, rather than focusing on specific game design topics. They are Trigger Happy author Steven Poole, Leigh Alexander, and Brian Howe, whose parody article section "You're Playing It Wrong" began with the new redesign.
For example, controlled-release oxycodone (OxyContin) or morphine (MS-Contin) are intended to, via novel delivery mechanisms, permit pain relief for up to twelve hours with an active ingredient which only provides relief for 3 to 6 hours. However, the inherent variability amongst different people with respect to drug metabolism makes this task challenging.
Sources: en.wikipedia.org
Compute the potential energy stored in a perfect specimen under a uniaxial tensile load. Fix the boundary so that the applied load does no work and then introduce a crack into the specimen. The crack relaxes the stress and hence reduces the elastic energy near the crack faces. On the other hand, the crack increases the total surface energy of the specimen. Compute the change in the free energy (surface energy − elastic energy) as a function of the crack length. Failure occurs when the free energy attains a peak value at a critical crack length, beyond which the free energy decreases as the crack length increases, i.e. by causing fracture. Using this procedure, Griffith found that
A number of health benefits of tocotrienols have been proposed, including decreased risk of age-associated cognitive impairment, heart disease and cancer. Reviews of human research linked tocotrienol treatment to improved biomarkers for inflammation and cardiovascular disease, although those reviews did not report any information on clinically significant disease outcomes. Biomarkers for other diseases were not affected by tocotrienol supplementation.
American kestrels are sexually mature by their first spring. In migratory populations, the males arrive at the breeding ground before females, then the female selects a mate. Pair bonds are strong, often permanent. Pairs usually use previous nesting sites in consecutive years. This gives birds an advantage over younger or invading individuals, as they would already be familiar with the hunting grounds, neighbors, predators, and other features of the site. Males perform elaborate dive displays to advertise their territory and attract a mate. These displays consist of several climbs and dives, with three or four "klee" calls at their peaks. Females are promiscuous for about one to two weeks after their arrival at the nesting site. This is thought to stimulate ovulation. Food transfers from the male to the female occur from about four to five weeks prior to egg laying to one to two weeks after. American kestrels are cavity nesters, but they are able to adapt to a wide variety of nesting situations. They generally prefer natural cavities (such as in trees) with closed tops and tight-fitting entrances that provide for maximum protection of the eggs and young. Kestrels occasionally nest in holes created by large woodpeckers, or use the abandoned nests of other birds, such as red-tailed hawks, merlins, and crows. They have been recorded nesting on cliff ledges and building tops, as well as in abandoned cavities in cactuses. American kestrels also commonly utilize nesting boxes. Three to seven eggs (typically four or five) are laid approximately 24–72 hours apart.
C-reactive protein (CRP), a marker of systemic inflammation, is also increased in obstructive sleep apnea (OSA). CRP and interleukin-6 (IL-6) levels were significantly higher in patients with OSA compared to obese control subjects. Patients with OSA have higher plasma CRP concentrations that increased corresponding to the severity of their apnea-hypopnea index score. Treatment of OSA with CPAP (continuous positive airway pressure) significantly alleviated the effect of OSA on CRP and IL-6 levels.
== Availability == Chlordiazepoxide is available in various dosage forms, alone or in combination with other drugs, worldwide. In combination with clidinium as NORMAXIN-CC and in combination with dicycloverine as NORMAXIN for IBS, and with the tricyclic antidepressant amitriptyline as Limbitrol.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.